{"url_path":"/sec/nvax/8-k/2026-06-23/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-23","source_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001104659-26-076648-index.html","accession_number":"0001104659-26-076648","cik":"0001000694","ticker":"NVAX","issuer_name":"NOVAVAX INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001104659-26-076648-index.html","primary_entity_key":"0001000694","primary_entity_name":"NOVAVAX INC"},"word_count":353,"has_tables":true,"body_markdown":"**Item 5.07. Submission of Matters to a Vote of Security Holders.**\n\n \n\nOn June 18, 2026, Novavax, Inc. (the “Company”)\nheld its Annual Meeting, at which stockholders as of April 23, 2026 (the “Record Date”) were entitled to vote. As of the Record\nDate, there were 164,427,429 shares of the Company’s common stock, par value $0.01 (“Common Stock”) outstanding and\nentitled to vote at the Annual Meeting, of which 99,118,766 shares were present in person virtually or represented by proxy, constituting\na quorum on all matters voted upon. The final voting results for the proposals considered and voted upon at the Annual Meeting, each of\nwhich were described in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission\non April 27, 2026, are as follows:\n\n \n\n**Proposal 1**: Stockholders elected the following\nClass I nominees for director, each to serve a three-year term expiring at the 2029 Annual Meeting of Stockholders:\n\n \n\n**Name**\n \n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\nJohn C. Jacobs\n \n43,479,777\n \n27,127,783\n \n768,456\n \n27,742,750\n\nGregg H. Alton, J.D.\n \n41,352,504\n \n29,160,512\n \n863,000\n \n27,742,750\n\nRichard J. Rodgers\n \n42,600,088\n \n27,885,191\n \n890,737\n \n27,742,750\n\n \n\n**Proposal 2**: Stockholders approved, on an\nadvisory basis, the compensation of the Company’s named executive officers:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n35,779,461\n \n34,858,658\n \n737,897\n \n27,742,750\n\n \n\n**Proposal 3**: Stockholders approved the amendment\nand restatement of the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n38,225,768\n \n32,606,575\n \n543,673\n \n27,742,750\n\n \n\n**Proposal 4**: Stockholders approved the amendment\nand restatement of the Novavax, Inc. 2013 Employee Stock Purchase Plan:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n35,988,154\n \n33,864,973\n \n1,522,889\n \n27,742,750\n\n \n\n**Proposal 5**: Stockholders ratified the appointment\nof Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31,\n2026:\n\n \n\n**For**\n \n**Against**\n \n**Abstain**\n \n**Broker Non-Votes**\n\n72,876,827\n \n23,562,092\n \n2,679,847\n \n-\n\n \n\n \n\n \n\n \n\n**SIGNATURE**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \n**NOVAVAX, INC.**\n\n \n \n \n\nDate: June 23, 2026\n/s/ Mark J. Casey\n\n \nName:\nMark J. Casey\n\n \nTitle:\nExecutive Vice President, Chief Legal Officer and Corporate Secretary"}